A. D. Seidman

529 total citations
37 papers, 413 citations indexed

About

A. D. Seidman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. D. Seidman has authored 37 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in A. D. Seidman's work include Cancer Treatment and Pharmacology (24 papers), HER2/EGFR in Cancer Research (15 papers) and Breast Cancer Treatment Studies (12 papers). A. D. Seidman is often cited by papers focused on Cancer Treatment and Pharmacology (24 papers), HER2/EGFR in Cancer Research (15 papers) and Breast Cancer Treatment Studies (12 papers). A. D. Seidman collaborates with scholars based in United States, United Kingdom and Spain. A. D. Seidman's co-authors include Zuo‐Feng Zhang, William R. Fair, George J. Bosl, Paul Schultz, H.W. Herr, Dean F. Bajorin, Howard I. Scher, Douglas S. Scherr, Alison Conlin and C. Hudis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

A. D. Seidman

35 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. D. Seidman United States	12	270	132	99	92	62	37	413
Fai Chung United States	11	181 0.7×	118 0.9×	82 0.8×	23 0.3×	58 0.9×	11	353
Zubaida Fida Hussain Pakistan	12	154 0.6×	79 0.6×	74 0.7×	59 0.6×	89 1.4×	19	337
Vanesa Quiroga Spain	8	185 0.7×	88 0.7×	155 1.6×	85 0.9×	74 1.2×	39	316
Roma Parikh Israel	8	261 1.0×	160 1.2×	145 1.5×	45 0.5×	93 1.5×	19	440
Jonathan Derman France	6	300 1.1×	69 0.5×	128 1.3×	82 0.9×	63 1.0×	8	482
A. Heikkinen Finland	8	191 0.7×	90 0.7×	174 1.8×	136 1.5×	130 2.1×	9	420
Kumiko Umemoto Japan	11	237 0.9×	110 0.8×	100 1.0×	93 1.0×	51 0.8×	44	381
Begoña Pérez‐Valderrama Spain	13	148 0.5×	88 0.7×	220 2.2×	106 1.2×	155 2.5×	50	405
D Kamel Finland	10	162 0.6×	110 0.8×	92 0.9×	69 0.8×	119 1.9×	13	360
Maria Del Carmen Rodriguez Peña United States	16	138 0.5×	347 2.6×	193 1.9×	97 1.1×	223 3.6×	29	624

Countries citing papers authored by A. D. Seidman

Since Specialization

Citations

This map shows the geographic impact of A. D. Seidman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. D. Seidman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. D. Seidman more than expected).

Fields of papers citing papers by A. D. Seidman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. D. Seidman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. D. Seidman. The network helps show where A. D. Seidman may publish in the future.

Co-authorship network of co-authors of A. D. Seidman

This figure shows the co-authorship network connecting the top 25 collaborators of A. D. Seidman. A scholar is included among the top collaborators of A. D. Seidman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. D. Seidman. A. D. Seidman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brogi, Edi, Conleth G. Murphy, Matthew Johnson, et al.. (2011). Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Annals of Oncology. 22(12). 2597–2603. 30 indexed citations

Liu, Jingfeng, Kathy S. Albain, Stephen Chan, et al.. (2011). Evaluation of response rate and disease control rate as potential predictors of overall survival in anthracycline-pretreated women receiving first-line chemotherapy for metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). 2552–2552. 4 indexed citations

Gajria, Devika, Tari A. King, Harpreet K. Pannu, et al.. (2011). PD09-08: Combined Inhibition of mTORC1 with Temsirolimus and HER2 with Neratinib: A Phase I/II Study in Patients with Metastatic HER2−Amplified or Triple-Negative Breast Cancer.. Cancer Research. 71(24_Supplement). PD09–8. 14 indexed citations

Abbruzzi, A., Gabriella D’Andrea, Teresa Gilewski, et al.. (2010). Abstract P6-12-09: A Phase I-II Trial of Dasatinib (D) in Combination with Weekly (w) Paclitaxel (P) for Patients (Pts) with Metastatic Breast Carcinoma (MBC). Cancer Research. 70(24_Supplement). P6–12. 3 indexed citations

Chang, Jeff, A. Abbruzzi, Shanu Modi, et al.. (2010). Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC).. Journal of Clinical Oncology. 28(15_suppl). TPS124–TPS124. 2 indexed citations

Mallam, Divya, Shekhar Patil, Jamie M. Howard, et al.. (2010). Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study.. Journal of Clinical Oncology. 28(15_suppl). 1589–1589. 5 indexed citations

Broadwater, Gloria, Paula N. Friedman, D. A. Berry, et al.. (2009). Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840.. Cancer Research. 69(2_Supplement). 6046–6046. 1 indexed citations

Conlin, Alison, C. Hudis, A M Bach, et al.. (2009). Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1006–1006. 23 indexed citations

Conlin, Alison, Gabriella D’Andrea, C. Hudis, et al.. (2008). Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT). Journal of Clinical Oncology. 26(15_suppl). 1086–1086. 23 indexed citations

10.

Conlin, Alison, Ming Hsu, Komal Jhaveri, et al.. (2008). Clinical and pathologic correlates in breast cancer (BC) brain metastasis (BM): Tissue microarray (TMA) studies. Journal of Clinical Oncology. 26(15_suppl). 1039–1039. 1 indexed citations

11.

Deng, Gang, A. D. Seidman, Gabriella D’Andrea, et al.. (2008). A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients. Journal of Clinical Oncology. 26(15_suppl). 3024–3024. 3 indexed citations

12.

Conlin, Alison, A. D. Seidman, Mary Ellen Moynahan, et al.. (2007). Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report. Journal of Clinical Oncology. 25(18_suppl). 1104–1104. 8 indexed citations

13.

Naughton, Michelle J., et al.. (2006). Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology. 24(18_suppl). 674–674. 2 indexed citations

14.

Seidman, A. D., Gloria Broadwater, L. G. Dressler, et al.. (2005). Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840. Journal of Clinical Oncology. 23(16_suppl). 558–558. 2 indexed citations

15.

Seidman, A. D.. (2001). Breast disease. Introduction.. PubMed. 14. 1–1. 1 indexed citations

16.

Seidman, A. D., Clifford A. Hudis, George Raptis, et al.. (1997). Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.. PubMed. 11(3 Suppl 2). 20–8. 15 indexed citations

17.

Hudis, Clifford A., A. D. Seidman, George Raptis, et al.. (1996). Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.. PubMed. 23(1 Suppl 1). 58–64. 26 indexed citations

18.

Seidman, A. D., José Baselga, George Raptis, et al.. (1995). Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.. PubMed. 22(6 Suppl 15). 18–23. 19 indexed citations

19.

Schultz, Paul, H.W. Herr, Zuo‐Feng Zhang, et al.. (1994). Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.. Journal of Clinical Oncology. 12(7). 1394–1401. 116 indexed citations

20.

Seidman, A. D., et al.. (1991). The evolving role of chemotherapy for muscle infiltrating bladder cancer.. PubMed. 18(6). 585–95. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact